Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8+ tumor-infiltrating lymphocytes in ovarian cancer

John R Webb; Katy Milne; Brad H Nelson

doi:10.4161/onci.27668

Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8⁺ tumor-infiltrating lymphocytes in ovarian cancer

Oncoimmunology. 2014 Jan 10:3:e27668. doi: 10.4161/onci.27668. eCollection 2014.

Authors

John R Webb¹, Katy Milne², Brad H Nelson³

Affiliations

¹ Trev and Joyce Deeley Research Centre; British Columbia Cancer Agency; Victoria, BC Canada ; Department of Biochemistry and Microbiology; University of Victoria; Victoria, BC Canada.
² Trev and Joyce Deeley Research Centre; British Columbia Cancer Agency; Victoria, BC Canada.
³ Trev and Joyce Deeley Research Centre; British Columbia Cancer Agency; Victoria, BC Canada ; Department of Biochemistry and Microbiology; University of Victoria; Victoria, BC Canada ; Department of Medical Genetics; University of British Columbia; Vancouver, BC Canada.

Abstract

Although high levels of tumor-infiltrating lymphocytes (TILs) generally correlate with good prognosis in high-grade serous ovarian cancer (HGSC) patients, little is known about the phenotype or specificity of these cells. We have recently demonstrated that TIL expressing the intra-epithelial lymphocyte marker CD103 (official name, integrin α_E, ITGAE) abundantly infiltrate HGSCs, strongly correlating with increased disease-specific survival.

Keywords: CD103; cancer; epithelium; tumor-infiltrating lymphocytes.